Clinical Trials in Swindon, United Kingdom
14 recruiting
Showing 1–17 of 17 trials
Recruiting
Phase 2
Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity
Primary Sjögren's Syndrome
Immunovant Sciences GmbH180 enrolled121 locationsNCT06979531
Recruiting
Inari VISION Registry
Pulmonary Embolism
Inari Medical1,000 enrolled10 locationsNCT06600542
Recruiting
Phase 3
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
Heart FailureAcute Heart Failure
Colorado Prevention Center5,200 enrolled299 locationsNCT06008197
Recruiting
Phase 3
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company410 enrolled116 locationsNCT05511363
Recruiting
Phase 3
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
Heart FailureHeart Failure With Reduced Ejection Fraction
Cytokinetics1,800 enrolled185 locationsNCT06736574
Recruiting
Phase 3
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
Kidney Disease, Chronic
Boehringer Ingelheim11,000 enrolled452 locationsNCT06531824
Recruiting
Phase 3
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company800 enrolled416 locationsNCT05980949
Recruiting
Phase 3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
HypertensionHigh Risk Cardiovascular DiseaseHigh Cardiovascular Risk
Alnylam Pharmaceuticals11,000 enrolled597 locationsNCT07181109
Recruiting
Phase 3
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
Pulmonary Hypertension Associated With HFpEF
Tenax Therapeutics, Inc.540 enrolled92 locationsNCT07288398
Recruiting
Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine
Migraine
AbbVie1,000 enrolled111 locationsNCT06543914
Recruiting
Not Applicable
"Physiological vs Right Ventricular Pacing Outcome Trial Evaluated for bradyCardia Treatment" (PROTECT-HF)
Left Bundle Branch Area PacingRight Ventricular PacingHis Bundle Pacing+2 more
Imperial College London2,600 enrolled45 locationsNCT05815745
Recruiting
Phase 2
Use of a Novel SUBCUTaneous Preparation of Furosemide to Facilitate Early Supported Discharge of Patients With Heart Failure
Heart Failure
NHS Greater Glasgow and Clyde170 enrolled22 locationsNCT05419115
Recruiting
European TauroPace Registry - University of Schleswig-Holstein Prospective Observational Clinical Study
CIED Related Infection
University of Kiel2,300 enrolled8 locationsNCT04735666
Recruiting
Clinical and Immunogenetic Characterization of Giant Cell Arteritis (GCA) and Polymyalgia Rheumatica (PMR)
Giant Cell ArteritisPolymyalgia Rheumatica
University of Leeds4,500 enrolled76 locationsNCT04102930
Recruiting
Not Applicable
Physiological Versus Right Ventricular Outcome Trial Evaluated for Bradycardia Treatment Upgrades
Heart FailurePacing-Induced Cardiomyopathy
Imperial College London155 enrolled12 locationsNCT06052475
Recruiting
Phase 3
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Community-acquired Pneumonia, Influenza, COVID-19
UMC Utrecht20,000 enrolled408 locationsNCT02735707
Recruiting
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
Huntington’s Disease
CHDI Foundation, Inc.35,000 enrolled183 locationsNCT01574053